ClinicalTrials.gg
RecruitingNCT01297400Updated Mar 16, 2026

Phase 2 Pilot Study of the Safety and Efficacy of Topical MW-III in Thermal Burns

A Phase 2 interventional study of Investigational Drug, MW-III and Silvadene® Cream 1% [Silver Sulfadiazine] in Burns, sponsored by Skingenix, Inc.. Recruiting at 6 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-03-16.

Sponsored by Skingenix, Inc. · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Started Mar 2022; still recruiting 4 years 8 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
60
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 336 studies in Burns with a site in United States — 40 open to participants now, 52 under way, 5 of them phase 3. Burns · United States.

Planned enrollment
59th of 272
60 · median 26
Started
2022
with 12 others
Phase 2
32 of 336
3 open now
Primary completion
2026-12
later than 18 of 51 live
Registered
116th of 336
by date

Among the 336 studies in Burns with a site in United States, this one is the 59th largest by planned enrollment of the 272 interventional ones that give a count, is one of 13 that started in 2022, is one of 32 in phase 2, reaches primary completion later than 18 of the 51 other live ones, and was the 116th registered.

Burns

906 studies on the registry are indexed under Burns; 165 are open to participants now.

Browse Burns studies →

Open to participants now

40 of the 336 studies in Burns with a site in United States are open now. Recruiting first, the newest first:

35 more — sign in →

All 40 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 85 Burns studies recruiting now, 38 (45%) set no upper age limit and 38 (45%) stop at 75 or younger; 17 take children under 18; 10 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 336 studies in Burns with a site in United States, or all of them as a file.
02

Study summary

To compare MW-III to Silvadene® Cream 1% (Silver Sulfadiazine) with respect to "time to healing" (≥95% re-epithelialization) of a partial thickness target thermal burn.

Read the detailed description

This phase 2 pilot study will assess the safety and efficacy of topical MW-III on thermal burns.

03

Conditions studied

  • Burns

Browse trials for

Keywords

  • Burns, Partial Thickness Burns
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Adults, 18 years of age or older on the day of signing the .
  2. Thermal Burns not exceeding a total body surface area (TBSA) OF 25%, with at least one partial thickness burn of 0.5% TBSA or greater. If full thickness burn(s) are present at screening, the total full thickness burn area shall not exceed 10% TBSA. Note: TBSA excludes areas of superficial (first degree) burns.
  3. Able and willing to give informed consent and comply with study procedures.

Exclusion criteria

Exclusion Criteria:

  1. Any burn that at screening is:

    1. infected.
    2. circumferential or deemed, in the judgment of the investigator, at high risk for developing compartment syndrome.
    3. partial thickness that is likely, in the judgment of the Investigator, to require grafting within 72 hours, or other non-protocol intervention.
  2. Severe inhalation injury or other significant non-burn trauma.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
60 participants (estimated)

Study arms

  • Experimental
    Investigational Drug, MW-III

    Investigational Drug, MW-III

    Drug: Investigational Drug, MW-III

  • Active comparator
    Standard of care

    Silvadene® Cream 1% \[Silver Sulfadiazine\]

    Drug: Silvadene® Cream 1% [Silver Sulfadiazine]

Interventions

06

What researchers measure

Primary outcomes

  1. Time to healing (≥95% re-epithelialization) of the partial thickness target burn.

    Time to healing (≥95% re-epithelialization) of the partial thickness target burn.

    Time frame: 28 days Treatment Period

Secondary outcomes

  1. Proportion of subjects with partial thickness burns that are healed at each scheduled study assessment.

    Proportion of subjects with partial thickness burns that are healed at each scheduled study assessment.

    Time frame: 28 days Treatment Period

  2. Proportion of subjects with partial thickness burns determined by PI to require skin grafting of burn wound by Day 28.

    Proportion of subjects with partial thickness burns determined by PI to require skin grafting of burn wound by Day 28.

    Time frame: 28 days Treatment Period

  3. Scar scores (POSAS) of the partial thickness target burn and all other partial thickness burns at Day 28.

    Scar scores (POSAS) of the partial thickness target burn and all other partial thickness burns at Day 28.

    Time frame: 28 days Treatment Period

07

Study locations

6 of 6 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2022 (actual). Primary completion is estimated for Dec 2026, 57 months after the start.

Of 17 phase 2 interventional studies under Burns, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 61. This study's planned 57 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 14, 2011
First posted
Feb 16, 2011
StartActual
Mar 11, 2022
Primary completionEst.
Dec 31, 2026
CompletionEst.
Dec 31, 2026
Last update
Mar 16, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 16, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01297400
Lead sponsor
Skingenix, Inc.
Responsible party
Sponsor
First posted
Feb 16, 2011
Start date
Mar 11, 2022
Primary completion
Dec 31, 2026 (estimated)
Completion
Dec 31, 2026 (estimated)
Last update
Mar 16, 2026

Study contacts

Vicki Christodoulou, MS, JD
Contact
vickic@skingenixusa.com
909-587-1650
Eric Wang, MD
Contact
ericw@skingenixusa.com
909-587-1650
Kevin Foster
principal investigator · Valleywise Health Medical Center

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Drugs, Investigational

Start the discussion